Product Name: Riociguat
Chemical Name: methyl (4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)(methyl)carbamate
SMILES Code: O=C(OC)N(C1=C(N)N=C(C2=NN(CC3=CC=CC=C3F)C4=NC=CC=C42)N=C1N)C
CAS NO: 117772-70-0 Product: Pixantrone
Synonym: BAY 63-2521; BAY 632521
Chemical Formula: C20H19FN8O2
Appearance: Solid powderMedchemexpress
Purity: 98% (this data is for the first batch)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 8211; 4 C for short term (days to weeks) or -20 C for long term (months to years).Sirtuin inhibitors
Solubility: Soluble in DMSO, not in water
Background Description: Riociguat (BAY 63-2521) is a novel drug that is currently in clinical development by Bayer. It is a stimulator of soluble guanylate cyclase (sGC). At the moment Phase III clinical trials investigate the use of riociguat as a new approach to treat two formPubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/10455251
Related Posts
Product Name: Riociguat
Chemical Name: methyl (4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)(methyl)carbamate
SMILES Code: O=C(OC)N(C1=C(N)N=C(C2=NN(CC3=CC=CC=C3F)C4=NC=CC=C42)N=C1N)C
CAS NO: 268203-93-6 Product: Tamsulosin (hydrochloride)
Synonym: BAY 63-2521; BAY63-2521; BAY632521
Chemical Formula: C20H19FN8O2
Appearance: Solid powderMedchemexpress.com
Purity: 98% (this data is for the first batch)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 8211; 4 C for short term (days to weeks) or -20 C for long term (months to years).Integrin inhibitors
Solubility: Soluble in DMSO, not in water
Background Description: Riociguat (BAY 63-2521) is a novel drug that is currently in clinical development by Bayer. It is a stimulator of soluble guanylate cyclase (sGC). At the moment Phase III clinical trials investigate the use of riociguat as a new approach to treat two formPubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/12954804